Lack of Long-Term Safety Data : Since many of the studies are short-term or the treatments are innovative (like dual GLP-1/GIP agonism), there is limited long-term safety data available, which is crucial to identifying potential chronic side effects or complications
Our medical professionals perform thorough evaluations before prescribing any medication and provide continuous monitoring throughout the process
3.4 Risk of bias in included studies The risk of bias in the included studies were assessed as Figs 3 and 4
Federici M, Porzio O, Zucaro L, Giovannone B, Borboni P, Marini MA, Lauro D, Sesti G
Hng Dn S Dng Kem Dng Trng Da Glutathione Sur.Petit t hiu qu dng trng v phc hi tt nht, hy s dng Kem Dng Trng Da Glutathione Sur.Petit ng cch: Bc 1: Ra mt sch s bng sa ra mt ph hp, lau kh nh nhng
Theres evidence suggesting there may be potential slight worsening of diabetic retinopathy with semaglutide, a 2023 study found